CLPBY Stock - Coloplast A/S
Unlock GoAI Insights for CLPBY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.12B | $27.03B | $24.50B | $22.58B | $19.43B |
| Gross Profit | $2.68B | $18.27B | $16.33B | $15.53B | $13.31B |
| Gross Margin | 65.1% | 67.6% | 66.6% | 68.8% | 68.5% |
| Operating Income | $1.12B | $7.32B | $6.77B | $6.44B | $6.36B |
| Net Income | $538.02M | $5.05B | $4.78B | $4.71B | $4.83B |
| Net Margin | 13.0% | 18.7% | 19.5% | 20.8% | 24.8% |
| EPS | $0.24 | $2.25 | $2.22 | $2.22 | $2.27 |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Visit WebsiteEarnings History & Surprises
CLPBYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $0.09 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.09 | $0.07 | -26.0% | ✗ MISS |
Q3 2025 | Aug 19, 2025 | $0.02 | $0.06 | +235.2% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.01 | $0.06 | +333.5% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $0.08 | $0.07 | -12.5% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $0.09 | $0.08 | -6.6% | ✗ MISS |
Q3 2024 | Aug 20, 2024 | $0.09 | $0.08 | -8.7% | ✗ MISS |
Q2 2024 | May 7, 2024 | $0.08 | $0.08 | 0.0% | = MET |
Q1 2024 | Feb 28, 2024 | $0.08 | $0.08 | +0.7% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $0.09 | $0.08 | -12.2% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.09 | $0.09 | -0.6% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $0.09 | $0.08 | -10.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $0.09 | $0.08 | -12.1% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | $0.08 | $0.08 | -5.8% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $0.08 | $0.09 | +5.2% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $0.08 | $0.07 | -17.1% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $0.09 | $0.09 | -2.4% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | — | $0.10 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.09 | — | — |
Latest News
Coloplast Sees FY2026 Sales $4.541B-$4.585B vs $4.650B Est
📉 NegativeColoplast Q4 Adj. EPS $0.07 Down From $0.08 YoY, Sales $1.090B Up From $1.024B YoY
➖ NeutralColoplast Q3 Adj. EPS $0.06 Down From $0.08 YoY, Sales $1.057B Up From $993.512M YoY
➖ NeutralFrequently Asked Questions about CLPBY
What is CLPBY's current stock price?
What is the analyst price target for CLPBY?
What sector is Coloplast A/S in?
What is CLPBY's market cap?
Does CLPBY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CLPBY for comparison